Antimicrobial Agents Practice Questions

Q: Which nucleoside reverse transcriptase inhibiting drug is a guanosine analogue?

Abacavir. **Explanation:** **Correct Answer: C. Abacavir** Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are prodrugs that require intracellular phosphorylation to their active triphosphate forms. They act as competitive inhibitors of HIV-1 reverse transcriptase. **Abacavir** is the only clinically used NRTI that is a **guanosine analogue**. It is unique because its conversion to the active form (carbovir triphosphate) involves a complex pathway involving adenosine deaminase. **Analysis of Incorrect Options:** * **A. Ritonavir:** This is a **Protease Inhibitor (PI)**, not an NRTI. It is primarily used in low doses as a "pharmacokinetic enhancer" (booster) because it potently inhibits the CYP3A4 enzyme, increasing the plasma levels of other PIs. * **B. Zidovudine (AZT):** This was the first NRTI developed. It is a **thymidine analogue** (along with Stavudine). Its dose-limiting toxicity is bone marrow suppression (anemia/neutropenia). * **D. Acyclovir:** While Acyclovir is a guanosine analogue, it is an **anti-herpes drug**, not an NRTI used for HIV. It inhibits viral DNA polymerase rather than reverse transcriptase. **High-Yield NEET-PG Pearls:** 1. **Analogue Classification:** * **Thymidine:** Zidovudine, Stavudine. * **Cytidine:** Lamivudine, Emtricitabine. * **Adenosine:** Didanosine (Tenofovir is an adenosine *nucleotide* analogue). * **Guanosine:** Abacavir. 2. **Genetic Testing:** Before starting Abacavir, patients must be screened for the **HLA-B*5701** allele. Presence of this allele carries a high risk of a fatal multi-organ hypersensitivity reaction. 3. **Mnemonic:** "Abaca-**G**avir" for **G**uanosine.

Q: Testing of HLA-B*57:01 is recommended prior to the initiation of which anti-retroviral agent?

Abacavir. **Explanation:** The correct answer is **Abacavir (Option D)**. **Why Abacavir is correct:** Abacavir, a Nucleoside Reverse Transcriptase Inhibitor (NRTI), is associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)**. This reaction is strongly linked to the presence of the **HLA-B*57:01 allele**. In patients carrying this allele, abacavir binds to the HLA-B*57:01 molecule, altering the repertoire of self-peptides presented to T-cells, which triggers an autoimmune-like systemic response. Screening for this allele is mandatory before starting therapy; if positive, Abacavir is strictly contraindicated. **Why other options are incorrect:** * **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) due to UGT1A1 inhibition, but it does not require HLA testing. * **Nelfinavir (B):** An older Protease Inhibitor primarily associated with gastrointestinal side effects (diarrhea). * **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can cause skin rashes or Stevens-Johnson Syndrome (SJS) in rare cases, there is no specific HLA-B*57:01 association. **High-Yield Clinical Pearls for NEET-PG:** * **The "Re-challenge" Rule:** Never re-challenge a patient with Abacavir if they have previously experienced a hypersensitivity reaction, as the second exposure can lead to fatal anaphylaxis. * **Symptoms of Abacavir HSR:** Fever, rash, GI distress, and respiratory symptoms (usually occurring within the first 6 weeks). * **Other HLA Associations to Remember:** * **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (especially in Asian populations). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions.

Q: A contraindication to the use of ciprofloxacin is a history of:

Epilepsy. **Explanation:** **Ciprofloxacin**, a second-generation fluoroquinolone, is contraindicated in patients with a history of **epilepsy** or seizure disorders. **1. Why Epilepsy is the Correct Answer:** Fluoroquinolones act as **GABA (Gamma-Aminobutyric Acid) antagonists**. GABA is the primary inhibitory neurotransmitter in the brain. By displacing GABA from its receptors in the central nervous system (CNS), ciprofloxacin lowers the seizure threshold, potentially triggering convulsions. This neurotoxic effect is further potentiated if the patient is concurrently taking NSAIDs, which enhance the displacement of GABA. **2. Analysis of Incorrect Options:** * **B. Deep Vein Thrombosis (DVT):** Ciprofloxacin does not significantly affect the coagulation cascade or venous stasis. However, caution is advised in patients with cardiovascular risk factors due to the risk of aortic aneurysm/dissection. * **C. Gout:** Unlike diuretics or pyrazinamide, fluoroquinolones do not interfere with uric acid metabolism or excretion. * **D. G-6 PD Deficiency:** While some sulfonamides and nitrofurantoin cause hemolysis in G-6 PD deficiency, ciprofloxacin is generally considered safe, though rare cases of hemolysis have been reported. **Clinical Pearls for NEET-PG:** * **Black Box Warning:** Fluoroquinolones are associated with **tendonitis and tendon rupture** (most commonly the Achilles tendon). * **Cartilage Toxicity:** They are generally avoided in children (under 18) and pregnancy due to potential damage to growing cartilage (arthropathy). * **QT Prolongation:** They can cause a prolonged QT interval, increasing the risk of Torsades de Pointes. * **Drug Interaction:** They inhibit Cytochrome P450 (CYP1A2), which can increase levels of **Theophylline** and **Warfarin**.

Q: Ciprofloxacin acts on which of the following targets?

DNA gyrase. **Mechanism of Action: Fluoroquinolones** **Correct Answer: B. DNA gyrase** Ciprofloxacin is a second-generation fluoroquinolone. Its primary mechanism of action involves the inhibition of two key bacterial enzymes [1, 2, 3]: 1. **DNA Gyrase (Topoisomerase II):** This enzyme is responsible for introducing negative supercoils into the DNA to relieve the torsional stress caused during replication [1, 2]. Inhibition leads to double-stranded DNA breaks and cell death. This is the primary target in **Gram-negative** bacteria [2, 3]. 2. **Topoisomerase IV:** This enzyme helps in the separation of daughter chromosomes after replication. This is the primary target in **Gram-positive** bacteria [2]. **Analysis of Incorrect Options:** * **A. DNA histone proteins:** Bacteria do not possess histones; they use histone-like proteins (HU proteins) to package DNA. Fluoroquinolones do not target these. * **C. Cyclic AMP (cAMP):** cAMP is a secondary messenger involved in cell signaling. While some toxins (like Cholera toxin) affect cAMP levels, ciprofloxacin does not. * **D. mRNA polymerase:** This is the target of **Rifampicin**, which inhibits DNA-dependent RNA polymerase, thereby blocking transcription. **High-Yield Clinical Pearls for NEET-PG:** * **Spectrum:** Ciprofloxacin is highly active against aerobic Gram-negative bacilli, including *Pseudomonas aeruginosa* [1]. * **Adverse Effects:** * **Cartilage Damage:** Contraindicated in children and pregnancy due to the risk of arthropathy. * **Tendinitis:** Increased risk of Achilles tendon rupture (especially in elderly or those on steroids). * **QT Prolongation:** A class effect of fluoroquinolones. * **Drug Interactions:** Absorption is significantly reduced when taken with antacids, iron, or calcium (chelation).

Q: Which antibiotic inhibits protein synthesis by premature termination and structurally resembles amino acyl tRNA?

Puromycin. ### Explanation **Correct Answer: C. Puromycin** **Mechanism of Action:** Puromycin is a unique antibiotic produced by *Streptomyces alboniger*. It acts as a **structural analog of the 3' end of aminoacyl-tRNA** (specifically tyrosinyl-tRNA). During the elongation phase of protein synthesis, puromycin enters the **A-site** of the ribosome. The peptidyl transferase enzyme incorporates puromycin into the growing polypeptide chain. Because puromycin lacks the necessary chemical bond to attach the next amino acid, it causes **premature chain termination** and the release of incomplete polypeptides (peptidyl-puromycin). **Why other options are incorrect:** * **A. Tetracycline:** Inhibits protein synthesis by binding to the **30S subunit** and reversibly blocking the attachment of aminoacyl-tRNA to the A-site. It does not mimic tRNA or cause premature termination. * **B. Chloramphenicol:** Binds to the **50S subunit** and inhibits the enzyme **peptidyl transferase**, preventing the formation of peptide bonds. * **D. Erythromycin (Macrolide):** Binds to the **50S subunit** and inhibits **translocation** (the movement of mRNA and tRNA through the ribosome). **High-Yield Clinical Pearls for NEET-PG:** * **Selectivity:** Unlike most antibiotics, puromycin is **not clinically used** because it is non-selective; it inhibits protein synthesis in both **prokaryotes and eukaryotes**, making it highly toxic to humans. It is primarily used as a research tool. * **Mnemonic for 50S inhibitors:** "**C**lean **T**ag" (**C**hloramphenicol, **L**inezolid, **E**rythromycin/Macrolides, **A**nd **N**_one_, **T**elithromycin, **A**zithromycin, **G**liflozin—*wait*, simpler: **CCELM**: **C**hloramphenicol, **C**lindamycin, **E**rythromycin, **L**inezolid). * **Mnemonic for 30S inhibitors:** "**AT** 30" (**A**minoglycosides, **T**etracyclines).

Q: Anti-fungal drug Nikkomycin acts by?

Inhibiting cell wall synthesis. **Explanation:** **Nikkomycin** (specifically Nikkomycin Z) is an antifungal agent that acts by **inhibiting cell wall synthesis**. Its mechanism of action is unique: it acts as a competitive inhibitor of **Chitin Synthase**, the enzyme responsible for synthesizing chitin. Chitin is a vital structural polysaccharide in the fungal cell wall; its inhibition leads to osmotic instability and cell lysis. **Analysis of Options:** * **Option B (Correct):** Nikkomycin mimics the structure of UDP-N-acetylglucosamine (the substrate for chitin synthase), thereby blocking the formation of the fungal cell wall. * **Option A (Incorrect):** Ergosterol synthesis inhibition is the mechanism of **Azoles** (inhibit 14-alpha demethylase), **Allylamines** like Terbinafine (inhibit Squalene epoxidase), and **Polyenes** like Amphotericin B (which bind to ergosterol). * **Option C (Incorrect):** Nucleic acid synthesis is inhibited by **Flucytosine (5-FC)**, which is converted into 5-fluorouracil, interfering with DNA and RNA synthesis. * **Option D (Incorrect):** Interference with mitosis by binding to microtubules is the mechanism of **Griseofulvin**. **High-Yield Clinical Pearls for NEET-PG:** * **Echinocandins** (e.g., Caspofungin) also inhibit the cell wall but target **1,3-beta-D-glucan synthase**, not chitin. * Nikkomycin is particularly noted for its synergistic effect when used with Echinocandins or Azoles. * It has shown significant potential in treating **Coccidioidomycosis** (Valley Fever) and *Blastomyces*. * **Mnemonic:** "Nikko **Chit**-chats" (Nikkomycin inhibits **Chit**in).

Q: What is the drug of choice for Listeria monocytogenes?

Ampicillin. Listeria monocytogenes is a Gram-positive, facultative intracellular bacillus. It is a significant pathogen in neonates, the elderly, and immunocompromised patients, often causing meningitis and sepsis. Why Ampicillin is the Correct Answer: Ampicillin (often combined with Gentamicin for synergistic effects) remains the Drug of Choice (DOC) for Listeria. While most Cephalosporins are ineffective against Listeria (a classic "hole" in their spectrum), Ampicillin exhibits excellent bactericidal activity against this organism. It effectively penetrates the tissues and targets the penicillin-binding proteins of the bacteria. Analysis of Incorrect Options: * A. Amoxycillin: While pharmacologically similar to Ampicillin, it is primarily used for oral therapy. In clinical practice, Listeriosis usually presents as a severe systemic infection (meningitis/sepsis) requiring the parenteral administration and established efficacy profile of Ampicillin. * C. Vancomycin: Although Vancomycin covers many Gram-positive organisms, it is not the first-line treatment for Listeria. It is generally reserved for patients with severe beta-lactam allergies. * D. Amikacin: This is an Aminoglycoside. While Aminoglycosides (like Gentamicin) are used as adjuncts to Ampicillin for synergy, they cannot be used as monotherapy because they have poor intracellular penetration and are ineffective against Listeria on their own. High-Yield Clinical Pearls for NEET-PG: * The Cephalosporin Gap: Remember the mnemonic LAME (Listeria, Atypicals, MRSA, Enterococci) for organisms NOT covered by standard 1st–4th generation Cephalosporins. * Alternative: In patients with a life-threatening Penicillin allergy, Trimethoprim-Sulfamethoxazole (TMP-SMX) is the preferred alternative. * Transmission: Usually occurs via contaminated food (unpasteurized milk, soft cheeses, deli meats). * Tumbling Motility: A characteristic laboratory finding for Listeria at 25°C.

Q: Ibalizumab was approved by the FDA in April 2018 for which condition?

HIV. **Explanation:** **Ibalizumab** is a breakthrough medication approved by the FDA in 2018 for the treatment of **Multidrug-Resistant HIV-1 (MDR HIV-1)**. It is specifically indicated for heavily treatment-experienced adults who are failing their current antiretroviral regimen. **Why HIV is the correct answer:** Ibalizumab is a **humanized monoclonal antibody** that acts as a **Post-Attachment Inhibitor**. Unlike other entry inhibitors (like Maraviroc), it binds to domain 2 of the **CD4+ T-cell receptor**. This binding does not prevent HIV from attaching to the cell, but it creates a conformational change that blocks the viral envelope (gp120) from interacting with co-receptors (CCR5 or CXCR4), thereby preventing viral entry into the host cell. **Why other options are incorrect:** * **Tuberculosis (TB):** Treated with antitubercular drugs (ATD) like Rifampicin and Isoniazid. Monoclonal antibodies are not currently standard therapy for TB. * **Leprosy:** Managed with MDT (Multidrug Therapy) consisting of Rifampicin, Dapsone, and Clofazimine. * **Malaria:** Treated with Artemisinin-based combination therapies (ACTs) or older agents like Chloroquine and Quinine. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** It is administered **intravenously (IV)** every 14 days, making it unique among HIV medications which are typically oral. * **Mechanism:** Post-attachment inhibition (blocks gp120-co-receptor interaction). * **Target:** It binds to the **host CD4 receptor**, not the virus itself, yet it does not cause immunosuppression or deplete CD4 counts. * **Other Entry Inhibitors:** Compare with **Enfuvirtide** (Fusion inhibitor - binds gp41) and **Maraviroc** (CCR5 antagonist).

Q: Which of the following cephalosporins is not active against anaerobes?

Cefoperazone. **Explanation:** The core concept tested here is the **anti-anaerobic spectrum** of specific second-generation cephalosporins known as **Cephamycins**. **1. Why Cefoperazone is the correct answer:** Cefoperazone is a **third-generation cephalosporin**. While it has excellent activity against *Pseudomonas aeruginosa*, it lacks significant activity against anaerobes, particularly *Bacteroides fragilis*. It is primarily used for systemic Gram-negative infections and biliary tract infections (due to its high biliary excretion). **2. Why the other options are incorrect:** * **Cefoxitin, Cefotetan, and Cefmetazole:** These are technically **Cephamycins** (often grouped with second-generation cephalosporins). They possess a unique **7-alpha-methoxy group** that provides resistance to the beta-lactamases produced by anaerobic bacteria. They are the "exceptions" in the cephalosporin family because they have excellent activity against **anaerobes** (including *B. fragilis*). They are commonly used for surgical prophylaxis in abdominal and pelvic surgeries where anaerobic contamination is likely. **High-Yield Clinical Pearls for NEET-PG:** * **The "Tan Fox" Mnemonic:** Cefote**tan** and Cefo**x**itin are the classic anti-anaerobic cephalosporins. * **Disulfiram-like Reaction:** Cefoperazone and Cefotetan contain a **Methylthiotetrazole (MTT) side chain**, which can cause a disulfiram-like reaction with alcohol and hypoprothrombinemia (bleeding risk). * **Biliary Excretion:** Cefoperazone and Ceftriaxone are the two cephalosporins that do not require dose adjustment in renal failure as they are primarily excreted in bile. * **Pseudomonas coverage:** Cefoperazone and Ceftazidime (3rd gen) and Cefepime (4th gen) are the key cephalosporins active against *Pseudomonas*.

Question 1

Which nucleoside reverse transcriptase inhibiting drug is a guanosine analogue?

Accepted Answer

Abacavir

Answer

Ritonavir

Answer

Zidovudine

Answer

Acyclovir

Question 2

Testing of HLA-B*57:01 is recommended prior to the initiation of which anti-retroviral agent?

Accepted Answer

Abacavir

Answer

Atazanavir

Answer

Nelfinavir

Answer

Raltegravir

Question 3

A 5-year-old female presented to the emergency department with fever, headache, and confusion. A provisional diagnosis of bacterial meningitis was made. The patient had a severe allergic reaction to penicillin approximately six months prior. She was admitted and intravenous antibiotics were started. A few days later, her investigations revealed: Hemoglobin 6.0 g/L, Erythrocyte count 1.2 x 10^6/mm^3, Platelets 60,000/mm^3, Leukocyte count 1500/mm^3. Which of the following is the most likely drug responsible for the above findings?

Accepted Answer

Chloramphenicol

Answer

Gentamicin

Answer

Doxycycline

Answer

Vancomycin

Question 4

A contraindication to the use of ciprofloxacin is a history of:

Accepted Answer

Epilepsy

Answer

Deep vein thrombosis

Answer

Gout

Answer

G-6 PD deficiency

Question 5

Ciprofloxacin acts on which of the following targets?

Accepted Answer

DNA gyrase

Answer

DNA histone proteins

Answer

Cyclic AMP (cAMP)

Answer

mRNA polymerase

Question 6

Which antibiotic inhibits protein synthesis by premature termination and structurally resembles amino acyl tRNA?

Accepted Answer

Puromycin

Answer

Tetracycline

Answer

Chloramphenicol

Answer

Erythromycin

Question 7

Anti-fungal drug Nikkomycin acts by?

Accepted Answer

Inhibiting cell wall synthesis

Answer

Inhibiting ergosterol synthesis

Answer

Inhibiting nucleic acid synthesis

Answer

Interfering with mitosis

Question 8

What is the drug of choice for Listeria monocytogenes?

Accepted Answer

Ampicillin

Answer

Amoxycillin

Answer

Vancomycin

Answer

Amikacin

Question 9

Ibalizumab was approved by the FDA in April 2018 for which condition?

Accepted Answer

HIV

Answer

Tuberculosis (TB)

Answer

Leprosy

Answer

Malaria

Question 10

Which of the following cephalosporins is not active against anaerobes?

Accepted Answer

Cefoperazone

Answer

Cefotetan

Answer

Cefmetazole

Answer

Cefoxitin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?